Pembrolizumab is a humanized anti-PD-1 monoclonal antibody used in research to block the PD-1/PD-L1 interaction, thereby restoring T-cell-mediated tumor killing. It is widely applied in immuno-oncology research for both in vitro T-cell activation assays and in vivo preclinical cancer models.
Concentration:
26.7 mg/mL
Molecular Weight:
149 kDa
Purity:
99.70% (May vary between batches)
CAS Number:
[1374853-91-4]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted